Fig. 2From: Usefulness of procalcitonin at admission as a risk-stratifying biomarker for 50-day in-hospital mortality among patients with community-acquired bloodstream infection: an observational cohort studyKaplan–Meier analysis reporting the probability of survival without in-hospital mortality in the 452 studied patients according to baseline plasma procalcitonin quartilesBack to article page